menu

Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease – Neurology Module

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease – Neurology Module

0.50 credits
30 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Recently, Alzheimer’s Disease (AD) saw its first approvals for disease modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing. In particular, amyloid-related imaging abnormalities (ARIA), the most common adverse effects seen in DMT trials, are unique to this agent class, raising new questions and considerations across multiple medical specialties. As there is limited formal guidance on how to recognize and mange ARIA, this program employs experts in the fields of neurology, radiology, emergency medicine, and primary care to provide insight into how their fields are evolving to accommodate ARIA and to outline individual roles and best practices across specialties. This activity is part of a seriesof six distinct programs designed to introduce ARIA, detail its recognition and management in specific clinical settings, and ultimately optimize collaborative care.

    This activity focuses on the role of neurology clinicians including when to raise clinical suspicion of ARIA in the clinic, how to evaluate suspected ARIA, and what courses of action may be needed to treat/manage ARIA should it occur.

    Note that the core activity is supplemented by an interactive clinical summary designed specifically for neurology clinicians. This convenient, mobile-friendly tool was developed to assist clinicians in considering how best to implement ARIA guidelines into their own day-to-day practice.

  • Disclosure of Relevant Financial Relationships

    Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies relevant financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported relevant financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in an accredited continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality accredited continuing education activities that promote improvements or quality in health care and not the business interest of an ineligible company.

    Planners' and Managers' Disclosure
    Efficient LLC and Medical Education Resources' planners and managers have no financial relationships to disclose. 

    Faculty Disclosures

    DR. GALVIN REPORTED THE FOLLOWING FINANCIAL RELATIONSHIPS:
    CONSULTING FEES: Alpha Cognition, Biogen, Cognivue, Eisai, Eli Lilly, Genentech/Roche, Otsuka

    DR. TOLEDO HAS NO REPORTED FINANCIAL RELATIONSHIPS.

  • Target Audience

    This activity is intended for neurologists, nurse practitioners, physician assistants, and other healthcare professionals involved in the diagnosis and management of patients with AD neurobiology.

  • Learning Objectives

    • Outline individualized monitoring strategies (e.g., baseline and follow-up MRIs) for ARIA in patients prescribed amyloid-targeting DMT to ensure it is identified and managed in a timely manner
    • Identify both proactive and reactive management strategies that have been employed across different clinical and radiologic severities of ARIA, to maximize patient safety while minimizing the risk of unnecessary treatment change
  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Efficient LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    PHYSICIAN CREDIT
    Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    PHYSICIAN ASSISTANTS (PAs) CREDIT

    Medical Education Resources has been authorized by the American Academy of Physician Assistants (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.  This activity is designated for 0.5 AAPA Category 1 CME Credits.  Physician Assistants should only claim credit commensurate with the extent of their participation.

    CERTIFICATE OF PARTICIPATION FOR OTHER HEALTHCARE PROFESSIONALS
    A Certificate of Participation will be given upon completion of the enduring activity enabling participants to register their credit with the appropriate licensing boards or associations.

  • Disclaimer

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

    Disclaimer
    The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Efficient LLC, and/or Lilly. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

  • Provider(s)/Educational Partner(s)

     

    This activity is jointly provided by Medical Education Resources (MER) and Efficient LLC.

  • Commercial Support

    This activity is supported by an educational grant from Lilly.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Recently, Alzheimer’s Disease (AD) saw its first approvals for disease modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing. In particular, amyloid-related imaging abnormalities (ARIA), the most common adverse effects seen in DMT trials, are unique to this agent class, raising new questions and considerations across multiple medical specialties. As there is limited formal guidance on how to recognize and mange ARIA, this program employs experts in the fields of neurology, radiology, emergency medicine, and primary care to provide insight into how their fields are evolving to accommodate ARIA and to outline individual roles and best practices across specialties. This activity is part of a seriesof six distinct programs designed to introduce ARIA, detail its recognition and management in specific clinical settings, and ultimately optimize collaborative care.

    This activity focuses on the role of neurology clinicians including when to raise clinical suspicion of ARIA in the clinic, how to evaluate suspected ARIA, and what courses of action may be needed to treat/manage ARIA should it occur.

    Note that the core activity is supplemented by an interactive clinical summary designed specifically for neurology clinicians. This convenient, mobile-friendly tool was developed to assist clinicians in considering how best to implement ARIA guidelines into their own day-to-day practice.

  • Disclosure of Relevant Financial Relationships

    Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies relevant financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported relevant financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in an accredited continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality accredited continuing education activities that promote improvements or quality in health care and not the business interest of an ineligible company.

    Planners' and Managers' Disclosure
    Efficient LLC and Medical Education Resources' planners and managers have no financial relationships to disclose. 

    Faculty Disclosures

    DR. GALVIN REPORTED THE FOLLOWING FINANCIAL RELATIONSHIPS:
    CONSULTING FEES: Alpha Cognition, Biogen, Cognivue, Eisai, Eli Lilly, Genentech/Roche, Otsuka

    DR. TOLEDO HAS NO REPORTED FINANCIAL RELATIONSHIPS.

  • Target Audience

    This activity is intended for neurologists, nurse practitioners, physician assistants, and other healthcare professionals involved in the diagnosis and management of patients with AD neurobiology.

  • Learning Objectives

    • Outline individualized monitoring strategies (e.g., baseline and follow-up MRIs) for ARIA in patients prescribed amyloid-targeting DMT to ensure it is identified and managed in a timely manner
    • Identify both proactive and reactive management strategies that have been employed across different clinical and radiologic severities of ARIA, to maximize patient safety while minimizing the risk of unnecessary treatment change
  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Efficient LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    PHYSICIAN CREDIT
    Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    PHYSICIAN ASSISTANTS (PAs) CREDIT

    Medical Education Resources has been authorized by the American Academy of Physician Assistants (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.  This activity is designated for 0.5 AAPA Category 1 CME Credits.  Physician Assistants should only claim credit commensurate with the extent of their participation.

    CERTIFICATE OF PARTICIPATION FOR OTHER HEALTHCARE PROFESSIONALS
    A Certificate of Participation will be given upon completion of the enduring activity enabling participants to register their credit with the appropriate licensing boards or associations.

  • Disclaimer

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

    Disclaimer
    The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Efficient LLC, and/or Lilly. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

  • Provider(s)/Educational Partner(s)

     

    This activity is jointly provided by Medical Education Resources (MER) and Efficient LLC.

  • Commercial Support

    This activity is supported by an educational grant from Lilly.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule16 Jul 2024